Globe Life AI Stock Analysis
Want to see GL full AI Analyst Report?
Globe Life (GL) AI Stock Analysis
Globe Life
(NYSE:GL)
The score is supported primarily by strong financial quality (cash generation, ROE, and a healthy balance sheet) and reasonable valuation (low P/E). It is held back by weaker technical momentum and earnings-call risks tied to near-term margin volatility (health/Evri and claims disruption) and the reduced 2026 EPS guidance.
Globe Life Key Performance Indicators (KPIs)
Insurance Premium Revenue by SegmentShows the distribution of premium income across different insurance segments, highlighting which areas drive the most revenue and indicating potential growth or risk in specific markets.
Globe Life’s premium growth is increasingly driven by Health rather than Life: Life remains the larger, steady cash cow with slow, consistent gains, while Health has accelerated materially in the last few quarters and is shifting the premium mix. Annuities are immaterial. For investors that means topline momentum, but also greater exposure to health-claims volatility and regulatory/price-sensitivity risk—monitor underwriting margins and loss trends in upcoming reports to see if faster Health growth is profitable or simply volume expansion.
Globe Life (GL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $12.13B
- Dividend Yield
- 0.78%
- Average Volume (3M)
- 499.70K
- Price to Earnings (P/E)
- 10.6
- Beta (1Y)
- 0.43
- Revenue Growth
- 5.62%
- EPS Growth
- 8.90%
- Country
- US
- Employees
- 3,695
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Insurance - Life
Globe Life Business Overview & Revenue Model
Company Description
Globe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured in...
How the Company Makes Money
Globe Life makes money primarily by underwriting insurance and investing the premiums it collects. (1) Premium revenue: The core revenue stream is recurring premiums paid by policyholders for life and supplemental health policies. Premiums are priced...
Globe Life Earnings Call Summary
The call was broadly constructive. Management reported growth in operating income, total and health premiums, book value, sales activity, investment income, capital flexibility, and shareholder returns, while also outlining favorable claims experience, AI initiatives, Bermuda-related cash flow opportunities, and 2027 growth guidance. These positives were partially offset by a 2% decline in GAAP net income, lower 2026 EPS guidance, direct-to-consumer and American Income recruiting challenges, lower life and health margin metrics, CMS-related claims disruption, and significant volatility and losses at the early-stage Evri business.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Globe Life expects total premium revenue growth to be around 6.5%, life premium revenue growth between 2.5% to 2.75%, life underwriting margin of 44% to 45% of premium, health premium revenue growth around 15%, health underwriting margin growth in the range of 4.0% to 4.5%, health underwriting margin of 22% to 24% of premium, administrative expenses at approximately 7.3% of premium, American Income average producing agent count down around 5%, Liberty National up around 9%, Family Heritage up around 5%, net life sales approximately flat at American Income, up around 10% at Liberty National and down around 9% at Direct to Consumer, and net health sales down around 7% at Liberty National, up approximately 10% at Family Heritage and up around 45% at United American; net operating earnings per diluted share are expected in the range of $15.35 to $15.65, normalized EPS growth approximately 8%, net investment income growth around 4.5%, required interest growth around 3.5%, excess investment income growth of 10% to 11%, average yield on total long term investments approximately 5.51%, and share repurchases in the range of $725 million to $775 million. For full year 2027, the company expects net operating earnings per diluted share in the range of $16.10 to $17.10, representing an increase of 7% at the midpoint, total premium revenue growth of 6% to 8%, life premium revenue growth of 4%, health premium revenue growth of 13% to 15%, life underwriting margin of 42% to 45% of premium, health underwriting margin of 20% to 24%, health underwriting margin dollar growth of 7% to 9%, net investment income growth in the range of 2.5% to 3.5%, required interest growth in the range of 3.5% to 4.0%, average yield on total long term investments between 5.50% to 5.55%, parent excess cash flows approximately $850 million to $950 million, and a cash conversion ratio in the range of 70% to 75% of net operating income; 2027 sales growth is expected to be mid- to high-single-digit at American Income, low double digit at Liberty National and low single digit at Direct to Consumer for net life sales, and low double digit at Liberty National and Family Heritage and high single digit at United American for net health sales.
Globe Life Financial Statement Overview
Summary
Fundamentals are solid: steady multi-year revenue growth, consistently strong ROE, and robust cash generation with free cash flow tracking close to net income. The main risk is the noted TTM profitability step-down versus 2025, which could signal near-term margin pressure despite strong growth.
Income Statement
74PositiveBalance Sheet
80PositiveCash Flow
83Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.28B | 6.00B | 5.78B | 5.45B | 5.23B | 5.12B |
| Gross Profit | 1.33B | 2.00B | 1.87B | 1.64B | 1.54B | 1.69B |
| EBITDA | 596.82M | 1.59B | 1.45B | 1.30B | 1.19B | 1.36B |
| Net Income | 1.19B | 1.16B | 1.07B | 970.75M | 894.39M | 1.03B |
Balance Sheet | ||||||
| Total Assets | 30.57B | 30.81B | 29.08B | 28.05B | 25.99B | 29.77B |
| Cash, Cash Equivalents and Short-Term Investments | 17.23B | 18.05B | 17.41B | 18.06B | 16.71B | 21.47B |
| Total Debt | 2.99B | 2.63B | 2.74B | 2.12B | 2.08B | 2.03B |
| Total Liabilities | 23.95B | 24.84B | 23.77B | 23.56B | 22.04B | 21.13B |
| Stockholders Equity | 6.62B | 5.97B | 5.31B | 4.49B | 3.95B | 8.64B |
Cash Flow | ||||||
| Free Cash Flow | 1.33B | 1.25B | 1.33B | 1.43B | 1.39B | 1.40B |
| Operating Cash Flow | 1.41B | 1.40B | 1.40B | 1.48B | 1.42B | 1.44B |
| Investing Cash Flow | -946.00M | -643.62M | -641.52M | -926.15M | -943.01M | -913.37M |
| Financing Cash Flow | -515.51M | -768.05M | -715.84M | -541.49M | -492.45M | -523.60M |
Globe Life Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GL, the sentiment is Negative. The current price of 160.74 is below the 20-day moving average (MA) of 161.31, below the 50-day MA of 165.53, and above the 200-day MA of 160.31, indicating a neutral trend. The MACD of -1.46 indicates Negative momentum. The RSI at 46.54 is Neutral, neither overbought nor oversold. The STOCH value of 50.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GL.
Globe Life Risk Analysis
Globe Life disclosed 24 risk factors in its most recent earnings report. Globe Life reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksGlobe Life Peers Comparison
Overall Rating
PRI86Outperform
CNO74Outperform
AFL73Outperform
GL69Neutral
SNFCA61Neutral
UNM51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 86Outperform | $8.86B | 11.57 | 30.97% | 1.58% | 7.93% | 16.30% | |
| 74Outperform | $5.25B | 12.83 | 16.62% | 1.22% | 2.47% | 53.14% | |
| 73Outperform | $62.57B | 18.66 | 11.85% | 1.89% | -6.22% | -10.65% | |
| 69Neutral | $12.08B | 10.56 | 19.09% | 0.78% | 5.62% | 8.90% | |
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| 61Neutral | $244.72M | 6.04 | 8.21% | ― | -4.19% | 103.64% | |
| 51Neutral | $12.26B | 56.62 | 2.23% | 2.42% | -4.15% | -72.51% |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GL | Globe Life Inc. | 160.74 | 30.38 | 23.30% | |
| AFL | AFLAC Incorporated | 127.61 | 17.64 | 16.04% | |
| CNO | CNO Financial Group | 57.47 | 18.35 | 46.90% | |
| PRI | Primerica | 293.39 | 42.63 | 17.00% | |
| SNFCA | Security National Financial | 9.00 | 1.61 | 21.79% | |
| UNM | Unum Group | 79.84 | 5.67 | 7.65% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
